Improved prognosis assessment for patients with bladder carcinoma.
Urothelial carcinomas are heterogeneous diseases with an aggressive clinical potential. To date, the most used prognostic factors for bladder carcinomas are grade and stage, which are based on histopathological parameters that are often not reliable in predicting a clinical outcome. Here, we evaluated the clinical outcome of 100 patients with urothelial carcinomas with follow-up information for more than 2 years after surgery in relation to the expression of two cell surface antigens, ie, E-cadherin and autocrine motility factor receptor (AMF-R, gp78). Frozen bladder tissues were serially cut, stained either with hematoxylin and eosin for grading, with the anti-gp78 antibodies, or with anti-E-cadherin antibodies to determine level of expression. Of 63 patients presented at the time of diagnosis with pathological loss of E-cadherin associated with increased gp78 expression, 39 (62%) succumbed to tumor progression or death. Of 37 patients with normal E-cadherin and gp78 expression positive and negative, respectively, 36 (97%) had favorable disease outcomes (P < 0.0001). The results suggest that in bladder carcinomas abnormal expression of both E-cadherin and gp78 results in a poor disease outcome, independent of tumor stage and grade.
Otto
T
T
Clinic of Urology, University of Essen Medical School, Germany.
Bex
A
A
Schmidt
U
U
Raz
A
A
Rübben
H
H
D000367:Age Factors; D000368:Aged; D015415:Biomarkers / Q000032:analysis; D015820:Cadherins / Q000378:metabolism*; D018572:Disease-Free Survival; D006801:Humans; D011379:Prognosis; D060285:Receptors, Autocrine Motility Factor; D018121:Receptors, Cytokine / Q000378:metabolism*; D012737:Sex Factors; D044767:Ubiquitin-Protein Ligases; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000378:metabolism*
D015415:Biomarkers; D015820:Cadherins; D018121:Receptors, Cytokine; C555000:AMFR protein, human; D060285:Receptors, Autocrine Motility Factor; D044767:Ubiquitin-Protein Ligases